Cogent Biosciences, Inc. (COGT)

Cogent Biosciences reported strong Phase 3 PEAK GIST data for bezuclastinib, leading to a surge in shares. The company received Breakthrough Therapy Designation from the FDA for bezuclastinib in combination with sunitinib for GIST patients previously treated with imatinib. Cogent closed an upsized underwritten public offering, generating net proceeds of $215.8 million, and raised $39 million through its at-the-market (ATM) facility. There have been instances of insider selling, with Fairmount Healthcare Fund II selling 3.5 million shares in January 2026. Sell-side analysts have become more optimistic, with an average price target of $39.55 and a consensus rating of "Moderate Buy".

Cogent Biosciences does not experience traditional demand seasonality for its products and services, as its lead product candidates are still in clinical development. The demand for its future products is driven by the unmet medical needs of patients with genetically defined diseases. The company anticipates the commercial launch of bezuclastinib in the second half of 2026, following potential FDA approvals.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, particularly in oncology. The company develops novel small molecule therapeutics targeting specific genetic mutations underlying aggressive and rare cancers and other genetically driven diseases. Bezuclastinib (CGT9486) is a selective tyrosine kinase inhibitor in Phase 3 trials targeting mutations within the KIT receptor tyrosine kinase. CGT4859 is a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trials for patients with documented FGFR mutations. The company is also developing a portfolio of novel targeted therapies for mutations in FGFR2/3, ErbB2, PI3Kα, KRAS, and JAK2, with plans for Investigational New Drug (IND) submissions for pan-KRAS(ON) and JAK2 V617F inhibitors in 2026.

Cogent Biosciences, Inc. has its corporate headquarters in Waltham, Massachusetts, and a discovery organization in Boulder, Colorado.

Cogent Biosciences' brand reputation has been positively influenced by clinical development progress and regulatory achievements. Positive top-line results from pivotal trials for bezuclastinib in systemic mastocytosis and gastrointestinal stromal tumors have bolstered its scientific credibility. The granting of Breakthrough Therapy Designation and the FDA's agreement to Real-Time Oncology Review for bezuclastinib further enhance its reputation. Analyst ratings have generally been positive, with a "Moderate Buy" consensus.

Cogent Biosciences has a significant institutional ownership base, with 326 institutional owners and shareholders holding 83.63% of shares outstanding. Major institutional owners include Fmr Llc, Vanguard Group Inc., and BlackRock, Inc. Individual and insider ownership accounts for a smaller percentage of shares outstanding (0.57%).